Download PDF
Thromb Haemost 2000; 84(01): 145-146
DOI: 10.1055/s-0037-1613988
Letters to the Editor
Schattauer GmbH

Transient Inhibitors in the Recombinate Pup Study

C. Rothschild
1   From Hemophilia Center, Necker Hospital, Paris, France, USA
,
J. Gill
2   Comprehensive Center for Bleeding Disorders, Milwaukee, WI, USA
,
I. Scharrer
3   Hemophilia and Thrombophilia Center, J. W. Goethe-University Hospital, Frankfurt, Germany, USA
,
G. Bray
4   Baxter/Hyland Div, Glendale, CA, USA
,
the Recombinate PUP Study Group › Author Affiliations
Further Information

Publication History

Received 17 December 1999

Accepted after revision 13 March 2000

Publication Date:
10 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M. A multicentric study of recombinant Factor FVIII (Recombinate): safety, efficacy and inhihitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-35.
    PubMedGoogle Scholar
  • 2 Gruppo R, Chen H, Schroth P, Bray GL. for the Recombinate PUP Study Group. Safety and immunogenicity of recombinant Factor FVIII (Recombinate®) in previously untreated patients (PUPs): a 7.3 year update. Haemophilia 1998; 04: 291a.
    PubMedGoogle Scholar